Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

New England Journal of Medicine

Volumn 343, Issue 21, 2000, Pages 1520-1528

  Bombardier, Claire ^a,l   Laine, Loren ^b   Reicin, Alise ^c   Shapiro, Deborah ^c   Burgos Vargas, Ruben ^d   Davis, Barry ^e   Day, Richard ^f   Ferraz, Marcos Bosi ^g   Hawkey, Christopher J ^h   Hochberg, Marc C ⁱ   Kvien, Tore K ^j   Schnitzer, Thomas J ^k  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j DIAKONHJEMMET HOSPITAL   (Norway)

^k NORTHWESTERN UNIVERSITY   (United States)

^l INSTITUTE FOR WORK AND HEALTH   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; NAPROXEN; ROFECOXIB;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DRUG EFFECT; DRUG RESPONSE; DUODENUM BLEEDING; DUODENUM PERFORATION; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH HEMORRHAGE; STOMACH PERFORATION; TREATMENT OUTCOME;

ADULT; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DUODENAL OBSTRUCTION; FEMALE; GASTRIC OUTLET OBSTRUCTION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; PEPTIC ULCER; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0034707105     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011233432103     Document Type: Article

References (30)

1. Misoprostol for co-prescription with NSAIDs
2. Nonsteroidal anti-inflammatory drug gastropathy
3. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
4. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997
5. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease
6. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs
7. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system
8. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constinative and inducible cyclooxygenase
9. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
10. Kofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
11. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
12. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
13. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
14. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
15. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
16. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire
17. Regression models and life-tables
18. Partial likelihood
19. N, Genuine Bayer aspirin Morristown, J.: Bayer ConsUmer Care Division, 1999 (package insert)
20. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
21. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
22. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
23. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: A randomized controlled trial
24. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthitis: A prospective observational cohort study
25. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers
26. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: The Flurbiprofen French Trial
27. Cardiovascular safety profile of rofecoxib in controlled clinical trials